Goldman Sachs’s $4 target on RCKT

RCKT Rocket Pharmaceuticals Inc

$2.6 → $4 (+54%) by Oct 2027

Neutral · raises · said Oct 8, 2026 · 12-month default horizon

Open: judged on the close on Oct 8, 2027

The article this target came from

Goldman Sachs upgrades Rocket Pharmaceuticals stock rating on Danon disease drug progress

Investing.com · Oct 8, 2026

raised its price target to $4.00 from $3.00

Goldman Sachs’s track record → Rocket Pharmaceuticals Inc →

A fact about what Goldman Sachs published, as reported by Investing.com, not a recommendation from Dalsna Finance; Goldman Sachs is not affiliated with this site.

Full methodology: how targets are collected, scored, ranked and corrected, what each field means, and how to cite the data.